Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Operating Leases (2019 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Operating Leases for 7 consecutive years, with $139.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases rose 27.6% year-over-year to $139.7 million, compared with a TTM value of $139.7 million through Sep 2025, up 27.6%, and an annual FY2024 reading of $106.4 million, down 6.3% over the prior year.
  • Operating Leases was $139.7 million for Q3 2025 at Tandem Diabetes Care, roughly flat from $139.9 million in the prior quarter.
  • Across five years, Operating Leases topped out at $139.9 million in Q2 2025 and bottomed at $3.0 million in Q2 2022.
  • Average Operating Leases over 5 years is $94.3 million, with a median of $113.6 million recorded in 2023.
  • The sharpest move saw Operating Leases tumbled 91.81% in 2022, then skyrocketed 3846.67% in 2023.
  • Year by year, Operating Leases stood at $23.9 million in 2021, then skyrocketed by 416.36% to $123.5 million in 2022, then decreased by 8.06% to $113.6 million in 2023, then dropped by 6.3% to $106.4 million in 2024, then surged by 31.27% to $139.7 million in 2025.
  • Business Quant data shows Operating Leases for TNDM at $139.7 million in Q3 2025, $139.9 million in Q2 2025, and $123.0 million in Q1 2025.